Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     

  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     

  • Bitcoin GBP

    50,909.16
    +3,044.15 (+6.36%)
     

  • CMC Crypto 200

    1,359.39
    +82.41 (+6.45%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     
MONEY:

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

AstraZeneca boosts early respiratory medicine with Pieris deal

Reuters
FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London April 28, 2014. REUTERS/Stefan Wermuth/File Photo (Reuters)

LONDON (Reuters) - AstraZeneca boosted its early-stage respiratory medicine pipeline on Wednesday by signing a deal with Pieris Pharmaceuticals to develop novel inhaled drugs that could fight asthma in new ways. Pieris will get upfront and near-term milestone payments of $57.5 million and up to $2.1 billion if the experimental drugs go on to become commercially successful. Pieris will be responsible for advancing its preclinical lead candidate, PRS-060, into initial Phase I clinical trials in 2017, the two companies said. (Reporting by Ben Hirschler)